EP2029118A2 - Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale - Google Patents

Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale

Info

Publication number
EP2029118A2
EP2029118A2 EP07762826A EP07762826A EP2029118A2 EP 2029118 A2 EP2029118 A2 EP 2029118A2 EP 07762826 A EP07762826 A EP 07762826A EP 07762826 A EP07762826 A EP 07762826A EP 2029118 A2 EP2029118 A2 EP 2029118A2
Authority
EP
European Patent Office
Prior art keywords
oxcarbazepine
pharmaceutical composition
particles
composition according
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07762826A
Other languages
German (de)
English (en)
Inventor
Sigal Blau
Ilan Zalit
Gershon Kolatkar
Carolina Abrutzky Azaria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/350,606 external-priority patent/US20070178164A1/en
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP2029118A2 publication Critical patent/EP2029118A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to pharmaceutical formulations. More particularly, the present invention concerns formulations comprising oxcarbazepine and methods for preparing these pharmaceutical formulations. Considering the very close similarity between oxcarbazepine and carbamazepine, including their similar low solubility, the present invention is equally applicable to pharmaceutical formulations comprising carbamazepine.
  • Oxcarbazepine 10-oxo- 10, 11 -dihydro-5H-dibenz[b, fJazepine-5- carboxamide of the general formula:
  • TRILEPTAL ® for the treatment of epilepsy.
  • TRILEPTAL ® the pharmacological benefit of oxcarbazepine is primarily exerted through the 10-hydroxy metabolite of oxcarbazepine.
  • the metabolite blocks voltage sensitive sodium channels, which results in the stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the brain.
  • U.S. Pat. No. 5,658,900 incorporated herein by reference, further describes the use of oxcarbazepine to treat Parkinson's disease.
  • Oxcarbazepine an antiepileptic drug
  • Oxcarbazepine is a white to yellowish crystalline powder that is practically insoluble in water.
  • Schlutermann US patent application 2003/0190361 describes a formulation comprising oxcarbazepine of fine particle size and a narrow size distribution.
  • the particles are characterized as having a median particle size of approximately 2 to 12 microns and leave a maximum residue on a 40 micron sieve of up to 5%.
  • Schlutermann also describes a film-coated tablet comprising oxcarbazepine particles with the same characteristics.
  • EP0646374 describes a color stable formulation of oxcarbazepine, which is coated with two layers, wherein each layer contains white pigments.
  • a common method of grinding drugs employs a jet mill.
  • the jet mill uses compressed air to produce micronized particles from large dry particles.
  • the mill is designed in such a way that the powdered particles exit the milling chamber and are collected in a collection vessel. Waste of fine particles is also produced during the process and is collected in a filter bag. Grinding processes such as this for example are costly in both their investment, as grinding is a time consuming process, and in operating costs. In addition, such processes result in substantial losses of the drug during grinding.
  • safety considerations should be taken into account during the air jet milling, due to the active pharmaceutical ingredient (API) dust formation accompanying the process.
  • Sehgal et al. (WO/2002/094774) describes a method to enhance the dissolution rate of oxcarbazepine by adding a wetting agent into the formulation.
  • the addition of such wetting agent to the oxcarbazepine formulation enhances the dissolution rate in-vitro.
  • the present invention provides a process of preparing an oxcarbazepine formulation with a sufficiently high dissolution rate, suitable bioavailability, and bioequivalent to the marketed as TRILEPT AL ® .
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising, a) oxcarbazepine, and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution.
  • the broad particle size distribution may comprise a multi-modal oxcarbazepine particle size distribution.
  • a method for preparing a pharmaceutical composition of the invention comprising the steps of: a) providing oxcarbazepine having a broad particle size distribution; b) providing at least one excipient; c) combining the oxcarbazepine with the at least one excipient.
  • the method further comprises the steps of e) optionally mixing the final granulate blend with one or more excipients to form a tabletting mixture; f) pressing either the tabletting mixture or the final granulate blend into tablets; and optionally g) coating the tablets.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising, a) spray granulated oxcarbazepine, and b) at least one pharmaceutical excipient.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising, a) oxcarbazepine with broad particle size distribution, and b) at least one pharmaceutical excipient.
  • the oxcarbazepine in the composition has at least two populations of different particle sizes and at least one of the populations of oxcarbazepine particles comprises spray granulated oxcarbazepine.
  • a pharmaceutcial composition comprising a) oxcarbazepine having a broad particle size distribution; b) a hydrophilic polymer, preferably Hydroxypropylmethylcellulose (hypromellose, HPMC); and c) at least one pharmaceutical excipient, wherein the weight ratip of hydrophilic polymer to oxcarbazepine in the composition is from about 1 :3 to about 1:25.
  • the broad particle size distribution of oxcarbazepine is a multi-modal particle size distribution.
  • a pharmaceutical composition comprising a) oxcarbazepine having a broad particle size distribution; and b) at least one pharmaceutical excipient, wherein the pharmaceutical composition is bioequivalent to Trileptal®.
  • the broad particle size distribution of oxcarbazepine is a multi-modal particle size distribution.
  • a pharmaceutical composition comprising a) oxcarbazepine having a broad particle size distribution; and b) at least one pharmaceutical excipient, wherein the disintegration time of the pharmaceutical composition is less than about 30 minutes.
  • the broad particle size distribution of oxcarbazepine is a multimodal particle size distribution.
  • the method further comprises at least one of the following steps d) and e); d) mixing the oxcarbazepine mixture with one or more excipients and forming a final granulate; e) mixing the final granulate with one or more excipients to form a tabletting mixture; and then, f) pressing the tabletting mixture into tablets; and optionally g) coating the tablets.
  • the method further comprises the following steps c) optionally mixing the final granulate with one or more excipients to form a tabletting mixture; d) pressing the tabletting mixture into tablets; and optionally e) coating the tablets.
  • the method further comprises at least one of the following steps d) optionally mixing the oxcarbazepine mixture with one or more excipients and forming a final granulate; e) mixing the final granulate with one or more excipients to form a tabletting mixture; f) pressing the tabletting mixture into tablets; and optionally g) coating the tablets.
  • the method further comprises at least one of the following steps c) optionally mixing the granulate with one or more excipients to form a tabletting mixture; d) pressing the tabletting mixture into tablets; and optionally e) coating the tablets.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising oxcarbazepine with a broad particle size distribution and having a dissolution profile such that a) no more than about 30% of the total amount of oxcarbazepine is dissolved from the composition after 35 minutes of measurement in a dissolution apparatus; b) from about 30% to about 50%, preferably about 40% or more, of the total amount of oxcarbazepine is dissolved from the composition after 50 minutes of measurement in a dissolution apparatus; and c) from about 30% to about 50% of the total amount of oxcarbazepine is dissolved from the composition after 60 minutes of measurement in a dissolution apparatus system that simulates the gastrointestinal environment.
  • the present invention provides a method of treating a patient suffering from epileptic seizures or Parkinson's disease or neuropathic pain comprising administering a therapeutically effective amount of oxcarbazepine in a pharmaceutical composition comprising a multi-modal oxcarbazapine particle size distribution.
  • Figure 1 Dissolution profile of oxcarbazepine tablets (prepared according to examples 1 and 2) in comparison to a TRILEPTAL ® bioequivalent formulation under simulated gastrointestinal conditions.
  • Figure 2 Dissolution profile of oxcarbazepine tablets (prepared according to examples 3 and 4) in comparison to a TRILEPTAL ® bioequivalent formulation and a non-bioequivalent formulation (prepared according to example 7) under simulated gastrointestinal conditions.
  • Figure 3 Dissolution profile of oxcarbazepine tablets (prepared according to examples 5 and 6) in comparison to a TRILEPTAL ® bioequivalent formulation and a non-bioequivalent formulation (prepared according to example 7) under simulated gastrointestinal conditions.
  • Figure 4 Dissolution profile of oxcarbazepine tablets (prepared according to examples 8 and 9) in comparison to a TRILEPTAL ® bioequivalent formulation under simulated gastrointestinal conditions.
  • Figure 5 Dissolution profile of oxcarbazepine tablets (prepared according to examples 10 and 11) in comparison to a TRILEPT AL ® bioequivalent formulation and a non-bioequivalent formulation (prepared according to example 7) under simulated gastrointestinal conditions.
  • Figure 6 Dissolution profile of oxcarbazepine tablets (prepared according to examples 12 and 13) in comparison to a TRILEPTAL ® bioequivalent formulation and a non-bioequivalent formulation (prepared according to example 7) under simulated gastrointestinal conditions.
  • Figure 7 Dissolution profile of oxcarbazepine tablets (prepare according to examples 15 and 16) in comparison to a TRILEPTAL ® bioequivalent formulation and a non-bioequivalent formulation.
  • narrow particle size distribution means a particular particle size distribution wherein the difference in the value of d(0.5) and d(0.95) is greater than 38 microns, and the d(0.5) value is 35 microns or less.
  • the d-values may be determined by methods such as laser diffraction, sieving or other methods known in the art. For example, the value of d(0.95) may be estimated from the sieve size through which no more than 95% of the particles would pass.
  • d(0.5) (which may also be written as “d(v, 0.5)” or volume median diameter) represents the particle size (diameter) for which the cumulative volume of all particles smaller than the d(0.5) value in a population is equal to 50% of the total volume of all particles within that population.
  • the broad particle size distribution of oxcarbazepine may be characterized by having d(0.5) values ranging from 12 to 35 ⁇ m, preferably 13 to 30 ⁇ and more preferably from 14 to 25 ⁇ . In another embodiment, d(0.5) ranges from 0.01 ⁇ to 2.0 ⁇ (more preferably from 0.2 to 1.9 ⁇ and most preferably from 0.4 to 1.5 ⁇ ). In another embodiment, d(0.5) ranges from 2-12 ⁇ .
  • the d(0.95) is preferably greater than 40 ⁇ .
  • sieving of the population using a 40 ⁇ sieve results with residue of more than 5% on sieve.
  • the term "multi-modal particle size distribution" and "multi-modal oxcarbazepine particle size distribution” are meant to be understood as either, oxcarbazepine having a particular particle size distribution which is characterized in that a graphic plot of oxcarbazepine particle sizes by volume or weight, displays two or more peak particle sizes.
  • a multi-modal particle size distribution of oxcarbazepine may be prepared by mixing at least two populations of oxcarbazepine characterized by different particle size distributions.
  • the multi-modal particle size distribution of the present invention is a bi-modal particle size distribution.
  • the difference in the two modes of populations of oxcarbazepine particles is at least about 12 microns, preferably at least about 13 microns.
  • a particle size distribution as described in the present invention can be determined by various conventional methods of analysis, such as Laser light scattering, laser diffraction, sedimentation methods, pulse methods, electrical zone sensing, sieve analysis and optical microscopy (usually combined with image analysis).
  • the evaluation of particle size distribution of the multi modal particle size distribution can be performed by preparing a mix of multi oxcarbazepine particle size populations at appropriate ratio and analyze their particle size distribution by laser diffraction method.
  • Another option to evaluate the multi modal particle size distribution is by mathematical calculation of d(0.1), d(0.5) and d(0.9) which is performed by calculation of the PSD weighted mean (average) of each of the oxcarbazepine populations. See, e.g., Table 1.
  • large drug particles refers to populations having a d(0.5) of at least about 12 microns, preferably at least about 13 microns.
  • a population of large oxcarbazepine particles is characterized as a population selected from the group consisting of, a population of oxcarbazepine particles with a d(0.5) of at least 13 microns, a population of unground particles, particles that do not pass a 40 micron sieve, and mixtures thereof.
  • a population of large oxcarbazepine particles is characterized as a population having a d(0.5) oxcarbazepine particle size of at least about 13 microns, and the population of large oxcarbazepine particles comprises more than about 5% of particles that do not pass a 40 micron sieve.
  • sieving a population of large oxcarbazepine particles using a 40 micron sieve results in a residue of more than 5% on sieve or d(0.95) is greater than 40 microns.
  • this amount of residue on a 40 micron sieve is more than about 25%, more preferably more than about 50%, for such population of large oxcarbazepine particles.
  • the d(0.5) of oxcarbazepine of a population of large oxcarbazepine particles may preferably be at least 30 microns, more preferably at least 45 microns, even more preferably at least 55 microns.
  • a population of large oxcarbazepine particles may also be characterized by having d(0.5) values range from about 12 to 120 ⁇ , preferably from about 60 to 90 ⁇ .
  • the term "unground particles” refers to particles obtained from the synthesis of oxcarbazepine (the active pharmaceutical ingredient, API) that have not been exposed to grinding or have been exposed to only minimal grinding. Unground oxcarbazepine particles may have a d(0.5) of more than 13 microns. In one example, unground particles may be characterized by d(0.1), d(0.5) and d(0.9) of about 21, 71 and 248 microns.
  • small drug particles generally means populations of drug particles with d(0.5) values smaller than 6 microns, preferably smaller than 3 microns, more preferably smaller than 2 microns.
  • sieving of the same population using a 40 ⁇ m sieve results in a residue of less than 5% on the sieve or d(0.95) is less than 40 microns. . .
  • spray-granulated oxcarbazepine refers to granulated populations of oxcarbazepine particles that have been granulated by spraying an oxcarbazepine dispersion on a powder carrier.
  • An important aspect in formulating an oxcarbazepine dosage form for use in medical treatments is achieving an adequate dissolution rate of the poorly soluble active pharmaceutical ingredient oxcarbazepine from a pharmaceutical composition.
  • a dissolution rate similar to that of the TRILEPT AL ® bioequivalent formulation (the Trileptal® bioequivalent composition A) is achievable with formulations having oxcarbazepine comprising a broad particle size distribution.
  • Preferred embodiments of the present invention encompass pharmaceutical compositions comprising oxcarbazepine, preferably having a desired dissolution rate and bioavailability using a safer method with less dust formation during the grinding process and/or reduced grinding cost and loss of active pharmaceutical ingredient.
  • One embodiment of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising, a) oxcarbazepine, and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution.
  • the broad particle size distribution is a multi-modal oxcarbazepine particle size distribution.
  • the oxcarbazepine pharmaceutical composition of the present invention is characterized by its broad particle size distribution. Particle size distribution can be determined by various conventional methods of analysis, such as Laser light scattering, laser diffraction, sedimentation methods, pulse methods, electrical zone sensing, sieve analysis and optical microscopy (usually combined with image analysis).
  • the multi-modal oxcarbazepine particle size distribution in the pharmaceutical composition contains at least two populations of particles. Each of these populations differ in their median particle size (or volume median diameter) and have a distinct particle size distribution.
  • the pharmaceutical composition comprises two or more populations of oxcarbazepine particles wherein at least one of these populations is a population of large oxcarbazepine particles.
  • a population of large oxcarbazepine particles is characterized as a population selected from the group consisting of, a population of oxcarbazepine particles with a d(0.5) of at least 13 microns, a population of unground particles, particles that do not pass a 40 micron sieve, and mixtures thereof.
  • An embodiment of the invention includes a pharmaceutical compositions of the present invention comprising large oxcarbazepine particles in an amount between about 6% by weight, and about 49% by weight of the total amount of oxcarbazepine in the pharmaceutical composition.
  • the pharmaceutical compositions of the present invention comprises at least one population of small oxcarbazepine particles, wherein the oxcarbazepine d(0.5) particle size is smaller than about 6 microns, preferably smaller than about 3 microns, most preferably smaller than 2 micron.
  • Such pharmaceutical composition preferably comprises small oxcarbazepine particles in an amount from about 94% by weight, to about 60% by weight of the total amount of oxcarbazepine in the pharmaceutical composition.
  • the content of the small oxcarbazepine particles in the multi -modal pharmaceutical composition is adjusted to the content of the large oxcarbazepine particles.
  • the pharmaceutical composition comprises large oxcarbazepine particles in an amount from about 6% to about 40% by weight and small oxcarbazepine particles in an amount from about 94% to about 60% by weight of the total amount of oxcarbazepine in the pharmaceutical composition.
  • the pharmaceutical composition comprises large oxcarbazepine particles in an amount from about 10% to about 35% by weight, preferably in an amount selected from about 10 %, about 20% and about 35% by weight, and small oxcarbazepine particles in an amount from about 90% to about 65% by weight, preferably in an amount selected from about 90%, about 80%, and about 65% by weight, of the total amount of oxcarbazepine large particles.
  • a pharmaceutical composition of the present invention comprises large oxcarbazepine particles in an amount of between about 95% by weight and about 51% by weight of the total amount of oxcarbazepine in the pharmaceutical composition.
  • the pharmaceutical compositions of this embodiment of the present invention comprises at least one population of small oxcarbazepine particles, wherein the d(0.5) is smaller than about 6 microns, preferably smaller than about 3 microns, most preferably smaller than 2 micron.
  • such pharmaceutical compositions comprises small oxcarbazepine particles in an amount from about 5% to about 49% by weight.
  • the content of the small oxcarbazepine particles in the pharmaceutical composition is adjusted to the content of the large oxcarbazepine particles.
  • the pharmaceutical composition comprises large oxcarbazepine particles in an amount from about 90% to about 60% by weight and small oxcarbazepine particles in an amount from about 10% to about 40% by weight of the total amount of oxcarbazepine in the pharmaceutical composition. More preferably, the pharmaceutical composition comprises large oxcarbazepine particle in an amount from about 85% to about 65% by weight and small oxcarbazepine particles in an amount from about 15% to about 35% by weight of the total amount of oxcarbazepine large particles.
  • the population of oxcarbazepine particles has a d(0.5) of not more than 2 microns and has a minimum residue on a 40 micron sieve of more than 5%.
  • the population of oxcarbazepine particles has a d(0.5) of 2 to 12 microns and has a minimum residue on a 40 micron sieve of more than 5%.
  • the oxcarbazepine has a d(0.5) of not less than 13 microns and has a minimum residue on a 40 micron sieve of more than 5%.
  • Another embodiment of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising, a) oxcarbazepine, and b) at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a particle size distribution characterized by oxcarbazepine with d(0.5) values ranging from 13 to 40 microns and more than 5% residue on 40 micron sieve.
  • the oxcarbazepine can be from a single population of particles.
  • a pharmaceutical composition comprises spray granulated oxcarbazepine.
  • such pharmaceutical composition comprises a) oxcarbazepine; and b) at least one pharmaceutical excipient, wherein the oxcarbazepine has a broad particle size distribution.
  • the broad particle size distribution of the oxcarbazepine particles may be a multi-modal particle size distribution. As described such multi-modal particle size distribution comprises two or more populations of oxcarbazepine particles having a distinct particle size distribution.
  • a pharmaceutical composition of the present invention comprising spray granulated oxcarbazepine one or more of the populations of oxcarbazepine particles having distinct particle size distributions is spray granulated.
  • a pharmaceutcial composition comprising a) oxcarbazepine having a broad particle size distribution; b) a hydrophilic polymer; and c) at least one pharmaceutical excipient, wherein the weight ratio of the hydrophilic polymer to oxcarbazepine in the composition is from about 1:3 to about 1:25.
  • the hydrophilic polymer is preferably Hydroxypropylmethylcellulose (hypromellose, HPMC).
  • HPMC Hydroxypropylmethylcellulose
  • the bioavailability of an oral tablet may be influenced by disintegration and dissolution.
  • hydrophilic polymer In order to reduce disintegration time of oxcarbazepine formulations a defined amount of hydrophilic polymer was used when small oxcarbazepine is sprayed onto large oxcarbazepine particles in a spray granulation process.
  • a preferred ratio of hydrophilic polymer to oxcarbazepine is from about 1 :5 to about 1 :22, more preferably from about 1 :9 to about 1 :20.
  • the total amount of hydrophilic polymer in the pharmaceutical composition of the present invention can also be expressed as not more than about 120 mg, preferably from about 20 mg to about 120 mg, more preferably from about 20 mg to about 50 mg, most preferably from about 30 mg to about 45 mg.
  • the total amount of hydrophilic polymer in the pharmaceutical composition of the present invention is not more than about 15% by weight of the composition, more preferably from about 1% to about 15% by weight • of the composition, even more preferably about 2% to about 15% by weight of the composition, yet even more preferably from about 2% to about 12% by weight of the composition, even more preferably from about 2.5% to about 10% by weight of the composisition, most preferably from about 2.5% to about 5% by weight.
  • the total amount of hydrophilic polymer in the pharmaceutical composition is from about 2% to about 4% by weight of the composition.
  • the broad particle size distribution of oxcarbazepine is a multi-modal particle size distribution.
  • the oxcarbazepine of this embodiment of the present invention comprises at least one population of small particles.
  • This population of small oxcarbazepine particles may be spray granulated when preparing a pharmaceutical composition of the present invention.
  • at least one population of small oxcarbazepine particles is spray granulated.
  • the ratio of the amount of hydrophilic polymer to the amount of small oxcarbazepine particles in such spray granulate is from about 1 :3 to about 1 :20, preferably from about 1 :5 to about 1:18, more preferably from about 1 :9 to about 1:17.
  • the oxcarbazepine pharmaceutical compositions comprising a broad particle size distribution as in the present invention further may contain excipients such as tablet and capsule fillers and diluents (such as microcrystalline cellulose, lactose, starch and tri-basic calcium phosphate), disintegrants (such as starch, croscarmellose sodium and sodium starch glycolate), binders (such as starch, hydroxypropyl methyl cellulose and Povidone), glidant (such as colloidal silicon dioxide), lubricants (such as magnesium stearate, magnesium lauryl sulfate and sodium stearyl fumarate) and surfactants and wetting agents (such as sodium lauryl sulfate, polysorbate and poloxar ⁇ er).
  • excipients such as tablet and capsule fillers and diluents (such as microcrystalline cellulose, lactose, starch and tri-basic calcium phosphate), disintegrants (such as starch, croscarmellose sodium and
  • suitable diluents and fillers for use in the pharmaceutical composition of the present invention include microcrystalline cellulose (e.g. Avicel ® ), ' microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
  • microcrystalline cellulose e.g. Avicel ®
  • lactose lactose
  • starch pregelatinized starch
  • calcium carbonate calcium sulfate
  • sugar dextrates
  • dextrin dextrin
  • dextrose dibasic calcium phosphate dihydrate
  • tribasic calcium phosphate kaolin
  • magnesium carbonate magnesium oxide
  • suitable surfactants for use in the pharmaceutical composition of the invention include poloxamers, polyethylene glycols, polysorbates, sodium lauryl sulfate, polyethoxylated castor oil, and hydroxylated castor oil.
  • Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
  • Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel ® ), hydroxypropyl methyl cellulose (e.g. Methocel ® ), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Povidone PVP K-30, Kollidon ® , Plasdone ® ), pregelatinized starch, sodium alginate and starch.
  • carbomer e.g. carbopol
  • a compacted solid pharmaceutical composition may also include the addition of a disintegrant to the composition.
  • Disintegrants include croscarmellose sodium (e.g. Ac Di Sol ® , Primellose ® ), crospovidone (e.g. Kollidon ® , Polyplasdone ® ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g. Explotab ® , Primoljel ® ) and starch.
  • Glidants can be added to improve the flowability of a non compacted solid composition and to improve the accuracy of dosing.
  • Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
  • a lubricant can be added to the composition to reduce adhesion and/or ease the release of the product from e.g. the dye.
  • Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • excipients that may be incorporated into the formulation include preservatives, antioxidants, or any other excipient commonly used in the pharmaceutical industry.
  • the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, and rectal administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
  • the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
  • the present invention also discloses a method for the production of oxcarbazepine pharmaceutical composition with broad particle size distribution, e.g. one of the methods comprises a first step of mixing large oxcarbazepine particles with small oxcarbazepine particles. This mixing can be carried out either prior to granulation or during granulation.
  • At least part of the large size oxcarbazepine particles for example at least one population of large oxcarbazepine particles
  • at least part of the small size oxcarbazepine particles for example at least one population of small oxcarbazepine particles
  • the process involves milling and optionally de- agglomerating a portion of the total amount of oxcarbazepine to form small drug particles.
  • the remaining amount of oxcarbazpine is not milled and used as such forming a population of large drug particles.
  • this remaining amount of oxcarbazepine is only slightly milled forming large drug particles of the multi-modal pharmaceutical composition of the present invention. This slightly milled portion of oxcarbazepine retains a large particle size distribution.
  • Various known methods can be used for milling and de- agglomeration of oxcarbazepine particles.
  • a jet mill, impact mill, ball mill, vibration mill, mortar mill or pin mill may for example be used for milling unground oxcarbazepine.
  • the oxcarbazepine is milled in a liquid dispersion by a homogenizer, such as rotor-stator or high pressure homogenizer such as a microfluidizer®, which produces milled oxcarbazepine at a high yield.
  • a homogenizer such as rotor-stator or high pressure homogenizer such as a microfluidizer®, which produces milled oxcarbazepine at a high yield.
  • a hydrophilic polymer or stabilizer is a hypromellose (Hydroxypropylmethylcellulose, HPMC), for example Pharmacoat®.
  • the method of the present invention produces compressed solid dosage forms.
  • a wet granulate can be prepared using a mixer and subsequently the wet granulate is dried in order to obtain a dry homogenous granulate.
  • a wet granulate is prepared by spray granulation.
  • spray granulation process particles and granulate are built up in a fluid bed by spraying a liquid onto fluidized particles.
  • a solution is sprayed through a nozzle.
  • the pharmaceutical composition of the present invention may be prepared in any dosage form such as a compressed granulate in the form of a tablet for example. Also, uncompressed granulates and powder mixes that are obtained by the method of the present invention in the pre-compression steps can be simply provided in dosage form of a capsule or sachet. Therefore, dosage forms of pharmaceutical composition of the present invention include solid dosage forms like tablets, powders, capsules, sachets, troches and losenges.
  • the dosage form of the present invention may also be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell.
  • the shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
  • the production of the pharmaceutical composition comprising a broad particle size distribution of oxcarbazepine comprises spray granulation of at least one population of oxcarbazepine particles, either from small drug particles or from large drug particles.
  • the process comprises spray granulation of both a population of small and large drug particles together.
  • a suitable dissolution rate and bioavailability obtained at reduced grinding cost, higher safety and less loss of active pharmaceutical ingredient are achieved by using pharmaceutical compositions comprising spray-granulated oxcarbazepine.
  • Spray-granulated particles are described in various publications, e.g. on the website of Glatt, a manufacturer of spray granulation equipment.
  • spray-granulated oxcarbazepine is a product of spraying a dispersion of oxcarbazepine particles on air-fiuidized excipient particles.
  • the sprayed oxcarbazepine dispersion comprises relatively large oxcarbazepine particles.
  • These relatively large particles comprise oxcarbazepine particles as may be obtained from synthesis without being milled, for example particles characterized with d(0.1), d(0.5) and d(0.9) of about 21, 71 and 248 microns, respectively, or those which have been subjected to only minimal grinding.
  • Relatively large particles for use in spray granulation may also be described as particles with a d(0.5) size greater than 13 microns, or oxcarbazepine particles that do not pass a 40 micron sieve.
  • the pharmaceutical composition of spray granulated oxcarbazepine also comprises oxcarbazepine particles of smaller size which are spray granulated.
  • the oxcarbazepine dispersion for use in spray granulation has a multi-modal oxcarbazepine particle size distribution similar to the oxcarbazepine in a multi-modal oxcarbazepine pharmaceutical composition.
  • the sprayed oxcarbazepine dispersion comprises relatively small oxcarbazepine particles.
  • These relatively small particles comprise oxcarbazepine particles as are obtained, for example, following a grinding process.
  • such dispersion of relatively small oxcarbazepine particles is obtained by providing a dispersion comprising relatively large oxcarbazepine particles and reducing the particle size of the oxcarbazepine particles in the dispersion, preferably by a high pressure homogenization process.
  • Relatively small particles for use in spray granulation may also be described as particles with a d(0.5) size smaller than 6 microns, preferebly smaller than 3 microns.
  • the pharmaceutical composition of spray granulated oxcarbazepine also comprises oxcarbazepine particles of larger size which are spray granulated.
  • the oxcarbazepine dispersion for use in spray granulation has a multi-modal oxcarbazepine particle size distribution similar to the oxcarbazepine in a multi-modal oxcarbazepine • pharmaceutical composition.
  • compositions of spray-granulated oxcarbazepine comprise at least one excipient selected from the group such as tablet and capsule fillers and diluents (such as microcrystalline cellulose, lactose, starch and tri-basic calcium phosphate), disintegrants (such as starch, croscarmellose sodium and sodium starch glycolate), binders (such as starch, hydroxypropyl methyl cellulose and Povidone), glidant (such as colloidal silicon dioxide), lubricants (such as magnesium stearate, magnesium lauryl sulfate and sodium stearyl fumarate) and surfactants and wetting agents (such as sodium lauryl sulfate, polysorbate and poloxamer).
  • the sprayed dispersion of oxcarbazepine comprises a binder, such as hypromellose (Hydroxypropylmethylcellulose, HPMC), for example Pharmacoat®.
  • the present invention also discloses a method for the production of a pharmaceutical composition of spray-granulated oxcarbazepine.
  • the method involves spraying of at least one excipient with a dispersion of oxcarbazepine.
  • the spraying process is preferably done by Fluidized bed technology equipment, where the particles are suspended in a vertical column with a rising air stream. While the particles are fluidized, the coating dispersion of oxcarbazepine is sprayed into the column.
  • This spraying can be carried out by any one of three methods; top spray, bottom spray and a "tangential" or powder spray.
  • the spraying of the oxcarbazepine dispersion is carried out by a top spray method.
  • the preferred spray-granulation method of the present invention differs somewhat from the commonly used spray-granulation method.
  • a granulation solution is sprayed onto a mixture of active and inactive materials which are suspended or fluidized in air.
  • a dispersion of the active material is sprayed on excipients suspended in air or on a mixture of active and inactive materials.
  • the pharmaceutical compositions of the present invention provide a dissolution rate for oxcarabzepine that is similar to a pharmaceutical composition comprising ground oxcarbazepine particles. This is in contrast to the expected dissolution rate for oxcarbazepine particles having a broad particle size distribution, because the pharmaceutical composition of the present invention comprises large/unground oxcarbazepine particles. Furthermore, the dissolution rate of oxcarbazepine from the pharmaceutical composition of the present invention is sufficient for gastro-intestinal absorption of oxcarbazpine in the slightly acidic and neutral pH region. Oxcarbazepine dissolves from the pharmaceutical composition of the present invention at a suitable rate.
  • At least 30% of the oxcarbazepine in the pharmaceutical composition dissolves from the composition in a simulated gastro-intestinal environment within 60 minutes. More preferably, at least 30% or more, preferably about 40% or more, of the oxcarbazepine in the pharmaceutical composition dissolves from the composition in such environment within 50 minutes, and most preferably at least 20% of the oxcarbazepine is dissolved from the pharmaceutical composition in such environment within 35 minutes.
  • the preferred dissolution rate for oxcarbazepine from the pharmaceutical composition of the present invention in a simulated gastro-intestinal environment may also be described as; a) no more than about 30% of the total amount of oxcarbazepine is dissolved from the composition after 35 minutes of measurement in a dissolution apparatus; b) from about 30%, or preferably about 40% or more, to about 50% of the total amount of oxcarbazepine is dissolved from the composition after 50 minutes of measurement in a dissolution apparatus; and c) from about 30% to about 50% of the total amount of oxcarbazepine is dissolved from the composition after 60 minutes of measurement in a dissolution apparatus.
  • the gastro-intestinal environment is simulated by using a physiological surfactant in a medium containing an acid such as HCl and a gradual addition of volume and a gradual pH change over time.
  • a physiological surfactant in a medium containing an acid such as HCl and a gradual addition of volume and a gradual pH change over time.
  • the simulated gastro-intestinal conditions maybe as described in Example 14 below.
  • compositions of the present invention provide a bioequivalent formulation to Trileptal®.
  • Pharmaceutical compositions of this embodiment of the present invention that are bioequivalent to Trileptal® comprise oxcarbazepine, a hydrophilic polymer and at least one pharmaceutical excipient, wherein the ratio of hydrophilic polymer to oxcarbazepine is from about 1 :3 to about 1 :25, preferably from about 1 :5 to about 1 :22, more preferably from about 1 :9 to about 1 :20.
  • the disintegration rate of oxcarbazepine from the pharmaceutical composition of the present invention is sufficiently reduced to minimize its influence on bioavailability.
  • the pharmaceutical composition comprising oxcarbazepine of the present invention has a suitable disintegration time as determined by the method described in the USP Pharmacopeia. (USP Pharmacopeia (2007); USP 30, NF 25, vol 1; ⁇ 701> Disintegration, pp 276-277).
  • disintegration time is less than about 30 minutes, more preferably less than about 20 minutes, most preferably less than about 15 minutes.
  • Oxcarbazepine is used for the treatment of epilepsy in patients suffering from epileptic seizures.
  • the pharmaceutical compositions of the present invention provide an effective delivery system for the administration of oxcarbazepine to patients in need of such treatment.
  • Treatment of patients suffering from epilepsy may comprise administering an effective amount of oxcarbazepine in a pharmaceutical composition of the present invention.
  • the pharmaceutical composition comprises a broad particle size distribution of oxcarabazepine, more preferably the broad oxcarbazepine particle size distribution is a multi- 5 modal oxcarbazepine particle size distribution, hi addition, oxcarbazepine has been shown to be effective to treat Parkinson's disease.
  • the pharmaceutical composition of the present invention therefore also provides an effective delivery system for the administration of oxcarbazepine to patients suffering from Parkinson's disease and neuropathic pains.
  • Formulations comprising oxcarbazepine with broad particle size distribution and at 1.5 least one pharmaceutical excipient were prepared.
  • Some of the examples below demonstrate the perpetration of multi-modal tablet formulations, hi order to evaluate the d(0.5) oxcarbazepine particle size distribution of the multi-modal formulation two optional strategies were performed; 1) multi-modal oxcarbazepine mixtures were prepared and their particle size distribution was analyzed using laser diffraction method (Malvern Mastersizer 0 S); or 2) mathematical calculation of d(0.1), d(0.5) and d(0.9) by the calculation of the PSD weighted mean of the large and small oxcarbazepine.
  • the following table describes for example a mathematical calculation of PSD of a multi-modal mixture containing small and large oxcarbazepine particles at a 35:65 ratio, respectively.
  • Example 1 Preparation of multi-modal oxcarbazepine formulation with a 10:90 ratio.
  • a preparation of a start dispersion from large Oxcarbazepine was prepared.
  • the Pharmacoat was added to the water and mixed until a clear mixture was obtained.
  • the large Oxcarbazepine was added into the Pharmacoat water mixture and dispersed using a rotor stator (Brogtec) for about 30 min.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a second step 2 the particle size of the large oxcarbazepine was reduced by a high pressure homogenization process (MFIC microfluidizer M-110Y).
  • MFIC microfluidizer M-110Y This particle size reduction by wet milling was carried out in the presence of a hydrophilic polymer or stabilizer as hypromellose (Hydroxy propyl Methyl Cellulose, for example Pharmacoat®).
  • a third step 3 the small Oxcarbazepine final dispersion was used as spray granulation dispersion in fluid-bed-top-spray-granulation process.
  • the granulate formulation contains the following substances:
  • a granulate of large Oxcarbazepine was prepared in a high sheer mixer.
  • the formulation of large oxcarbazepine granulate was as follows:
  • the final fifth step 5 involved the preparation of granulate mixture and tablets.
  • the sprayed granulate of step 3 was mixed together with the granulate of step 4 in a 9:1 ratio, respectively.
  • a mixture of the two granulates was prepared, wherein the sprayed granulate contained 540mg of active material and the granulate of step 4 • contained 60mg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • the granulate mixture was subsequently pressed into tablets and a dissolution was performed.
  • the observed dissolution rate was similar to that for the TRILEPT AL® bioequivalent formulation as is shown in figure 1.
  • the particle size of the oxcarbazepine used in this example was estimated to be such that d(0.5) is of the order of 0.6 microns and about 6% of this material would be retained on a 40 micron sieve.
  • the following exemplifies how such estimation is measured.
  • a mix of two dispersions was performed. The mix contains 90% of small particles characterized by d(0.5) of 0.7 micron and 10% of large particle size characterized by d(0.5) of 68 microns.
  • the d(0.5) of the mix as measured by malvern was 0.7 microns.
  • Example 2 Preparation of multi-modal oxcarbazepine formulation with a 1:5 ratio.
  • the first four steps were as in example 1.
  • the final step 5 of preparing a granulate mixture and tablets the sprayed granulate was mixed together with the granulate of step 4 in a 16.6:83.3 ratio, respectively.
  • preparing a 600mg dose a mixture of the two granulates was prepared, wherein the sprayed granulate contains 500mg of active material and the mixed- granulate contains lOOmg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • the granulate mixture was subsequently pressed into tablets and a dissolution was performed.
  • the observed dissolution rate was similar to that for the TRILEPTAL® bioequivalent formulation as is shown in figure 1.
  • the particle size of the oxcarbazepine used in this example was estimated to be such that d(0.5) is of the order of 0.7 microns and about 10% of this material would be retained on a 40 micron sieve. The following exemplifies how such estimation is measured.
  • a mix of two dispersions at a close ratio was performed.
  • the mix contains 80% of small particles characterized by d(0.5) of 0.7 micron and 20% of large particle size characterized by d(0.5) of 68 microns.
  • the d(0.5) of the mix as measured by malvem was 0.8 micron.
  • the d(0.5) of 1:5 ratio is even less than 0.8 micron.
  • analysis of large oxcarbazepine was performed by alpine.
  • the result of the sieve analysis demonstrates that about 60% of the oxcarbazepine is retained on the sieve. Therefore, a mix of 1 :5 will retain about 10% on a 40 micron sieve, assuming that no powder would be retained on 40 micron screen after sieving of the small oxcarbazepine particles.
  • Example 3 Preparation of multi-modal oxcarbazepine formulation with a 55:45 ratio using a combination of a sprayed granulate and mixed granulate.
  • the formulation of large oxcarbazepine granulate was as follows:
  • the final fifth step 5 involved the preparation of granulate mixture and tablets.
  • the sprayed granulate of step 3 was mixed together with the mixed-granulate of step 4 in a 45:55 ratio, respectively.
  • a mixture of the two granulates was prepared, wherein the sprayed granulate contains 270mg of active material and the mixed-granulate from step 4 contains 330mg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • the granulate mixture was subsequently pressed into tablets and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPT AL® bioequivalent formulation as is shown in figure 2.
  • Example 4 Preparation of multi-modal oxcarbazepine formulation with a 65:35 ratio using a combination of a sprayed granulate and mixed granulate.
  • the first four steps were as in example 3.
  • the final step 5 of preparing a granulate mixture and tablets the sprayed granulate was mixed together with the mixed-granulate in a 35:65 ratio, respectively.
  • a mixture of the two granulates was prepared, wherein the sprayed granulate (small) contains 210mg of active material and the mixed-granulate (large) from step 4 contains 390mg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • Example 5 Preparation of multi-modal oxcarbazepine formulation with a 65:35 ratio using a combination of two spray granulates.
  • step 5 the large Oxcarbazepine dispersion was used as spray granulation dispersion in a fluid-bed-top-spray-granulation process.
  • the granulate formulation contains the following substances:
  • the final sixth step 6 involved the preparation of granulate mixture and tablets.
  • the sprayed granulate of step 3 was mixed together with the sprayed-granulate of step 5 in a 35:65 ratio, respectively.
  • a mixture of the two granulates was prepared, wherein the sprayed granulate of step 3 contains 210mg of active material and the sprayed-granulate from step 5 contains 390mg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • the granulate mixture was subsequently pressed into tablets and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPTAL® bioequivalent formulation as is shown in figure 3.
  • Example 6 Preparation of multi-rnodal oxcarbazepine formulation with a 55:45 ratio using a combination of two spray granulates.
  • the first five steps were as in example 5.
  • the sprayed-granulate of step 3 was mixed together with the sprayed- granulate of step 5 in a 45:55 ratio, respectively.
  • preparing a 600mg dose a mixture of the two granulates was prepared, wherein the sprayed granulate of step 3 contains 270mg of active material and the sprayed-granulate from step 5 contains 330mg of active material. Consequently the final formulation, including a lubricant as an additional excipient, was as follows.
  • the granulate mixture was subsequently pressed into tablets and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPTAL® bioequivalent formulation as is shown in figure 3.
  • Example 7 Preparation of relatively slow dissolving pharmaceutical composition.
  • a non- bioequivalent formulation with relatively slow dissolving pharmaceutical composition was prepared with oxcarbazepine characterized by d(0.5) of 43 microns.
  • the oxcarbazepine granulate was prepared using high sheer mixer and dried by fluid bed drier.
  • the final formulation, including a lubricant as an additional excipient, was as follows.
  • the final blend was compressed into tablets and the tablets were coated.
  • Example 8 Preparation of sprayed granulated oxcarbazepine formulation.
  • a preparation of start dispersion from large Oxcarbazepine was prepared.
  • the Pharmacoat was added to the water and mixed until clear mixture was obtained.
  • the Large Oxcarbazepine was added into the Pharmacoat water mixture and dispersed using a rotor stator (Brogtec) for 30 min at 9000 rpm.
  • the Oxcarbazepine particle size distribution following rotor stator process as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • the granulate formulation contains the following substances:
  • the particle size of the oxcarbazepine used in this example was estimated to be such that d(0.5) is of the order of 27 microns and not less than about 29% of this material would be retained on a 40 micron sieve.
  • the following exemplifies how such estimation is reached.
  • Example 9 Preparation of sprayed granulated oxcarbazepine formulation with extra- granular excipients.
  • step 3 the oxcarbazepine sprayed granulate was mix together with extragranular excipients as follow:
  • Oxcarbazepine sprayed granulate from step 2 [contains 1659 mg 600mg oxcarbazepine (after potency adjustment)]
  • Magnesium stearate 10 mg In the fourth step The granulate mixture was subsequently pressed into tablets and a dissolution test was performed. The observed dissolution rate was similar to that for the TRILEPT AL® bio equivalent formulation as is shown in figure 4.
  • Example 10 Preparation of sprayed granulated oxcarbazepine formulation.
  • a preparation of a start dispersion from large Oxcarbazepine was prepared.
  • the Pharmacoat was added to the water and mixed until clear mixture was obtained.
  • the large Oxcarbazepine was added into the Pharmacoat water mixture and dispersed using a rotor stator (Brogtec) for 30 min at 9000rpm.
  • the large Oxcarbazepine particle size distribution following rotor stator process as measured by the laser diffraction method (Malvern Mastersiz ⁇ r S), was as follows:
  • the granulate formulation contains the following substances:
  • Example 11 Preparation of sprayed granulated oxcarbazepine formulation with extra- granular excipients.
  • step 3 the oxcarbazepine sprayed granulate was mix together with extragranular excipients as follows:
  • the granulate mixture was subsequently pressed into tablets and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPT AL® bio equivalent formulation as is shown in figure 5.
  • the particle size of the oxcarbazepine used is preferably such that the d(0.5) value is between about 13 microns and about 30 microns
  • Example 12 Preparation of multi-modal oxcarbazepine formulation with a 20:80 ratio wherein a dispersion of small particles of oxcarbazepine is sprayed onto large oxcarbazepine particles in a spray granulation process.
  • a preparation of a start dispersion from large Oxcarbazepine was prepared.
  • 150Og of Large Oxcarbazepine raw material was dispersed in a solution of 30Og hypromellose (Pharmacoat 603) in 600Og of purified water.
  • the Pharmacoat was added to the water and mixed until a clear mixture was obtained.
  • the large Oxcarbazepine was added into the Pharmacoat water mixture and dispersed using a rotor stator (Brogtec) for about 30 m ⁇ n.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a second step 2 the particle size of the large oxcarbazepine was reduced by a high pressure homogenization process (MFIC microfluidizer M-110Y).
  • MFIC microfluidizer M-110Y The particle size distribution of this final Oxcarbazepine (small) dispersion (small Oxcarbazepine), as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a third step 3 the small Oxcarbazepine final dispersion was used as spray granulation dispersion in fluid-bed-top-spray-granulation process and sprayed onto a mix of excipients and large oxcarbazepine.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as mentioned in stage 1 of the current example.
  • the granulate formulation contains the following substances:
  • this granulate was mixed together with extra-granular excipients as follows: Oxcarbazepine granulate (batch #16) 996 mg
  • the granulate mixture was subsequently pressed into tablets and a dissolution test was performed. Additionally, the tablets were coated.
  • the observed dissolution rate was similar to that for the TRILEPTAL® bioequivalent formulation as is shown in figure 6.
  • the particle size of the oxcarbazepine used in this example was estimated to be such that d(0.5) is of the order of 0.8 microns and about 12% of this material would be retained on a 40 micron sieve.
  • the evaluation of d(0.5) particle size and sieve analysis is demonstrated in example 2.
  • step 4 the oxcarbazepine sprayed granulate was mix together with extra-granular excipients as follows:
  • Oxcarbazepine granulate (batch #16) 996 mg
  • the granulate mixture was subsequently pressed into tablets and a dissolution was performed. Additionally, the tablets were coated.
  • the observed dissolution rate was similar to that for the TRILEPTAL® bioequivalent formulation as is shown in figure 6.
  • the particle size of the oxcarbazepine used in this example is similary estimated to be such that d(0.5) is of the order of 0.8 microns and about 12% of this material would be retained on a 40 micron sieve.
  • the tablets described in examples 1-13 were tested in a media containing a physiological surfactant and the procedure included gradual addition of volume and pH changes in order to simulate the gastrointestinal conditions.
  • the dissolution procedure was carried out in an USP Apparatus H, paddle method, at 37°C and 50 rpm under the following conditions as in Table 2.
  • the concentration of the dissolved oxcarbazepine was measured at the 35, 50, and 60 minute time periods. Due to the turbidity of lecithin solutions, the samples are preferably clarified before measurement by UV.
  • a pharmaceutical composition which is bioequivalent to TRILEPT AL ® was included in the dissolution experiments. Table 4 shows the observed dissolution profile for each of the tablets from examples 1-6, and 8-13, a TRILEPT AL ® bioequivalent tablet ("Trileptal® bioequivalent composition A”), and a relatively slow dissolving pharmaceutical composition prepared according to the present invention (example 7).
  • Figure 1 demonstrates the results of a dissolution test of the TRILEPTAL ® bioequivalent composition A versus Examples 1 and 2 under the above described conditions.
  • Figure 2 demonstrate a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relative slow composition (example 7) and Examples 3 and 4.
  • Figure 3 demonstrates the results of a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relative slow composition (example 7), and Examples 5 and 6 under the same dissolution conditions.
  • Figure 4 demonstrates the results of a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relative slow composition (example 7), and Examples 8 and 9 under the same dissolution conditions.
  • Figure 5 demonstrates the results of a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relativly slow composition (example 7), and Examples 10 and 11 under the same dissolution conditions.
  • Figure 6 demonstrates of a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relative slow composition (example 7), and Examples 12 and 13 under the same dissolution conditions.
  • Figure 7 demonstrates the results of a dissolution test of the TRILEPTAL ® bioequivalent composition A, the relative slow composition (example 7), and Examples 15 and 16 under the same dissolution conditions.
  • Table 3 Dissolution profiles of pharmaceutical compositions of oxcarbazepine.
  • the bioavailability of an oral tablet may be influenced by disintegration and dissolution.
  • disintegration and dissolution In order to reduce disintegration time of small particles in oxcarbazepine formulations a reduced amount of hypromellose was used when small oxcarbazepine is sprayed onto large oxcarbazepine particles in a spray granulation process with hypromellose.
  • the following two examples (15 & 16) demonstrate formulations with such reduced amount of hypromellose, which amount of hypromellose is less than in the above examples 1 to 13.
  • Example 15 Preparation of multi-modal oxcarbazepine formulation with a 20:80 ratio and 43.2mg hypromellose.
  • a preparation of a start dispersion from large Oxcarbazepine was prepared. 1800g of Large Oxcarbazepine raw material was dispersed in a solution of 162g hypromellose (HPMC, Pharmacoat 603) in 386Og of purified water. The Pharmacoat was added to the water and mixed until a clear mixture was obtained. Subsequently, the large Oxcarbazepine was added into the Pharmacoat water mixture and mixed well.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a second step 2 the particle size of the large oxcarbazepine was reduced by a high pressure homogenization process (MFIC microfluidizer M-110Y).
  • MFIC microfluidizer M-110Y The particle size distribution of this final Oxcarbazepine (small) dispersion (small Oxcarbazepine), as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a third step 3 the small Oxcarbazepine final dispersion was used as spray granulation dispersion in fluid-bed-top-spray-granulation process and sprayed onto a mix of excipients and large oxcarbazepine.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as mentioned in stage 1 of the current example.
  • the granulate formulation contains the following substances:
  • this granulate was mixed together with extra-granular excipients as follows:
  • the granulate mixture was subsequently pressed into tablets coated and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPT AL® bioequivalent formulation as is shown in figure 7.
  • the d(0.5) of oxcarbazepine used in this example as measured by laser diffraction method (Malvern Mastersizer S) is 0.90 micron and the amount retain on a 40 micron sieve is 13%.
  • Example 16 Preparation of multi-modal oxcarbazepine formulation with a 20:80 ratio and 30mg hvpromellose.
  • a preparation of a start dispersion from large Oxcarbazepine was prepared. 1800g of Large Oxcarbazepine raw material was dispersed in a solution of 113g hypromellose (Pharmacoat 603) in 380Og of purified water. The Pharmacoat was added to the water and mixed until a clear mixture was obtained. Subsequently, the large Oxcarbazepine was added into the Pharmacoat water mixture and mixed well.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a second step 2 the particle size of the large oxcarbazepine was reduced by a high pressure homogenization process (MFIC microfluidizer M-IlOY).
  • MFIC microfluidizer M-IlOY The particle size distribution of this final Oxcarbazepine (small) dispersion (small Oxcarbazepine), as measured by the laser diffraction method (Malvern Mastersizer S), was as follows:
  • a third step 3 the small Oxcarbazepine final dispersion was used as spray granulation dispersion in fluid-bed-top-spray-granulation process and sprayed onto a mix of excipients and large oxcarbazepine.
  • the large Oxcarbazepine particle size distribution as measured by the laser diffraction method (Malvern Mastersizer S), was as mentioned in stage 1 of the current example.
  • the granulate formulation contains the following substances:
  • this granulate was mixed together with extra-granular excipients as follows:
  • the granulate mixture was subsequently pressed into tablets coated and a dissolution test was performed.
  • the observed dissolution rate was similar to that for the TRILEPT AL® bioequivalent formulation as is shown in figure 7.
  • the d(0.5) of oxcarbazepine used in this example as measured by laser diffraction method (Malvern Mastersizer S) is 0.90 micron and the amount retain on a 40 micron sieve is 13%.
  • Example 17 Study of single dose, comparative bioavailability of a composition according to this invention compared with Trileptal® 600mg marketed composition
  • compositions according to the invention coated tablets prepared according to example 15.
  • Example 18 The disintegration time of the formulations was tested in water using disintegration apparatus (Disintegrator Erweka ZT41).
  • Example 19 Study of single dose, comparative bioavailability of Trileptal® bioequivelent composition A compared with Trileptal® 600mg marketed composition.
  • Trileptal® bioequivelent composition A Trileptal® bioequivelent composition A.
  • The_samples for pharmacokinetic analysis were collected in predetermined time intervals. Oxcarbazepine content in plasma was measured for each sample.
  • Example 20 Wet sieve method for determining the amount of Oxcarbazepine retained on a
  • Oxcarbazepine was weighed and poured on sieve.
  • Sieve-shaker was activated according to the parameters described above, and began the water flow.
  • the sieve (containing the remaining Oxcarbazepine) was dried in oven and the amount of Oxcarbazepine retained on the 40 ⁇ m sieve was weighed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant de l'oxcarbazépine et au moins un excipient pharmaceutique, l'oxcarbazépine ayant une large distribution granulométrique. La large distribution granulométrique de l'oxcarbazépine dans la composition pharmaceutique est de préférence une distribution granulométrique multimodale, de préférence présentant une meilleure vitesse de dissolution de l'oxcarbazépine.
EP07762826A 2006-01-31 2007-01-31 Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale Withdrawn EP2029118A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76413406P 2006-01-31 2006-01-31
US11/350,606 US20070178164A1 (en) 2006-01-31 2006-02-08 Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US86033306P 2006-11-20 2006-11-20
US89736107P 2007-01-24 2007-01-24
PCT/US2007/002882 WO2007089926A2 (fr) 2006-01-31 2007-01-31 Preparations pharmaceutiques de l'oxcarbazepine et procedes pour sa preparation

Publications (1)

Publication Number Publication Date
EP2029118A2 true EP2029118A2 (fr) 2009-03-04

Family

ID=38328068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07762826A Withdrawn EP2029118A2 (fr) 2006-01-31 2007-01-31 Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale

Country Status (6)

Country Link
EP (1) EP2029118A2 (fr)
JP (1) JP2008540346A (fr)
AU (1) AU2007211210A1 (fr)
CA (1) CA2634879A1 (fr)
IL (1) IL191922A0 (fr)
WO (1) WO2007089926A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178164A1 (en) * 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2014143935A1 (fr) * 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Company Forme posologique d'oxcarbazépine à dispersion rapide
JP6843498B2 (ja) * 2015-10-14 2021-03-17 Eaファーマ株式会社 錠剤、固体分散体顆粒及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354563A (en) * 1985-07-15 1994-10-11 Research Development Corp. Of Japan Water dispersion containing ultrafine particles of organic compounds
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
EA200301223A1 (ru) * 2001-05-18 2004-08-26 Рэнбакси Лабораториз Лимитед Лекарственные формы окскарбазепина
MXPA04011801A (es) * 2002-05-31 2005-09-12 Desitin Arzneimittel Gmbh Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa.
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US20090196919A1 (en) * 2004-10-25 2009-08-06 Ajay Singla Oxcarbazepine dosage forms
WO2007007182A2 (fr) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Formes galeniques solides d'agent antiepileptique
US20070178164A1 (en) * 2006-01-31 2007-08-02 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP2010499A4 (fr) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd Composition pharmaceutique d'oxcarbazepine à particules de 15 à 30 microns en moyenne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007089926A2 *

Also Published As

Publication number Publication date
JP2008540346A (ja) 2008-11-20
WO2007089926A2 (fr) 2007-08-09
AU2007211210A1 (en) 2007-08-09
IL191922A0 (en) 2009-08-03
WO2007089926A3 (fr) 2008-12-24
CA2634879A1 (fr) 2007-08-09

Similar Documents

Publication Publication Date Title
US20070178164A1 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
JP5484910B2 (ja) レバプラザン含有の固体分散体及びその製造方法
US20100166857A1 (en) Pharmaceutical dosage forms and methods of manufacturing same
US20060193910A1 (en) Tablets with improved drug substance dispersibility
CZ297251B6 (cs) Fenofibrátový prostredek s okamzitým uvolnováním,zpusob prípravy farmaceutického prostredku a suspenze fenofibrátu v mikronizované forme
WO1999016448A1 (fr) Comprime de theophylline a liberation prolongee
WO2010035282A1 (fr) Compositions pharmaceutiques comprenant du deferasirox
ZA200309289B (en) Oxcarbazepine dosage forms.
EP2886109A1 (fr) Particule creuse contenant un médicament
US20090196919A1 (en) Oxcarbazepine dosage forms
WO2013057741A2 (fr) Compositions pharmaceutiques d'acide ursodésoxycholique
US20140044780A1 (en) Extended-Release Levetiracetam and Method of Preparation
JP2004525887A (ja) 新規フェノフィブラート錠剤
EP2029118A2 (fr) Formulation pharmaceutique d'oxcarbazepine, et sa méthode de fabrication, caractérisée en ce que l'oxcarbazepine a une distribution de la taille des particules qui est large et multi-modale
EP2076248A2 (fr) Procédés et compositions pour contrôler la biodisponibilité de médicaments médiocrement solubles
CN101594850A (zh) 降血脂药物组合物和及其制备方法
AU2009337766B2 (en) Pharmaceutical formulation of nanonised fenofibrate
US20070248684A1 (en) Pharmaceutical formulations of oxcarbazepine and methods for its preparation
EP2190419A1 (fr) Système matriciel multiparticulaire contenant de la galantamine
JP2009510121A (ja) 医薬組成物
KR20060020681A (ko) 염산 베니디핀 함유 의약 조성물
US20090143360A1 (en) Oxcarbazepine Formulation
KR20070089188A (ko) 고상 제약 조성물
EP2044933A1 (fr) Système de matrice à multi-particules contenant de la galantamine
JP2007530702A (ja) 噴霧乾燥医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070928

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100803